Norrsken Mind awards EUR 1.1 million to support research & implementation of psychedelic therapies
Norrsken Mind has awarded EUR 1.1 million in 2025 to support eight psychedelic research and non profit initiatives across Europe. The funding covers clinical research, evidence generation, research infrastructure, practitioner training, and policy work linked to future implementation.
A central element of this portfolio is support for PAREA’s work on advancing early and responsible access to psychedelic therapies in the EU. Norrsken Mind is backing PAREA to engage with regulators and explore new regulatory approaches within EU pharmaceutical legislation.
This support enables PAREA to focus on practical policy design, evidence generation, and system readiness. The aim is to help ensure that emerging psychedelic therapies can move from research into healthcare in a way that is safe, evidence based, and scalable.
The funding package also includes support for Heal Ukraine Trauma, a PAREA community supporter, to expand group ketamine assisted psychotherapy training for mental health professionals working with war affected populations. Additional grants strengthen shared research infrastructure and improve standards for assessing evidence across the field.
Since 2023, Norrsken Mind has committed EUR 3.4 million to psychedelic research and non profit initiatives. This long term philanthropic engagement is helping build the scientific, regulatory, and healthcare foundations needed for responsible access to psychedelic therapies in Europe.
About Norrsken Mind
Norrsken Mind is a non-profit foundation dedicated to advancing psychedelic science in Europe. We fund high-quality research examining the therapeutic potential of psychedelics for mental health disorders, along with non-profit initiatives that help lay the foundation for the future integration of these treatments into healthcare. By mobilising philanthropic capital, offering grants, and facilitating partnerships, Norrsken Mind aims to create the conditions necessary for psychedelic treatments to be rigorously studied, responsibly implemented, and ultimately accessible to patients in need.
